Unicycive Therapeutics — Third Quarter 2026 Earnings Summary
Unicycive Therapeutics announced that the U.S. Food and Drug Administration accepted its New Drug Application resubmission for oxylanthanum carbonate, establishing a Prescription Drug User Fee Act target date of March 25, 2027. The company reported a net loss of $7.0 million for the third quarter ended September 30, 2026, driven primarily by increased commercial launch preparation expenses, while maintaining approximately $59 million in cash and marketable securities with a runway extending beyond 2027. Commercial readiness efforts are advancing through discussions with dialysis organizations and plans to hire a sales force in early 2027, supported by favorable reimbursement changes from the Centers for Medicare & Medicaid Services effective January 2027.
- Company
- UNICYCIVE THERAPEUTICS INC
- Sector
- Healthcare
- Industry
- Biotechnology